carboplatin + nedaplatin + paclitaxel + zoledronic acid

This is a combination regimen consisting of four drugs—carboplatin, nedaplatin, paclitaxel, and zoledronic acid—used primarily in the treatment of non-small cell lung cancer (NSCLC) with bone metastases. Carboplatin and nedaplatin are platinum-based chemotherapeutic agents that cause DNA crosslinking and inhibit DNA synthesis, leading to apoptosis in rapidly dividing cells. Paclitaxel is a microtubule inhibitor that stabilizes microtubules and prevents their depolymerization, thereby inhibiting cell division. Zoledronic acid is a bisphosphonate that inhibits osteoclast-mediated bone resorption, reducing skeletal-related events in patients with bone metastases. The combination has demonstrated effectiveness and tolerability for NSCLC patients with bone metastases[1][2][5]. Each component acts via independent mechanisms to target both tumor proliferation and complications from bone involvement.